Cancer anorexia is a negative prognostic factor and is broadly defined as the loss of the interest in food. However, multiple clinical domains contribute to the phenotype of cancer anorexia. The characterization of the clinical and molecular pathophysiology of cancer anorexia may enhance the efficacy of preventive and therapeutic strategies.
INTRODUCTION
The reduction of the interest in food, that is, anorexia, is a complex and potentially lethal syndrome whose pathophysiology is mainly related to profound alterations of the volitional and nonvolitional control of eating behavior. Anorexia may result from an altered perception of body image, which leads to the volitional refuse of food (i.e., primary anorexia or anorexia nervosa), or it may develop as a consequence of the increased and/or persistent inflammatory response secondary to acute and chronic diseases (i.e., secondary anorexia or disease-specific anorexia). In anorexia nervosa, appetite is suppressed by the psychiatric need to adjust body image to unrealistic models [1] . In secondary anorexia, appetite is suppressed by the functional disruption of the neuronal pathways regulating physiological eating behavior [2] .
In animal models and humans, the onset and progressive development of cancer is associated to a number of symptoms and signs collectively termed as 'sickness behavior'. This syndrome represents a highly evolutionary conserved behavior which confers survival advantage following trauma and acute stress [3] . However, its protective role during chronic diseases remains matter of debate. Anorexia is a key symptom of sickness behavior and may favor survival after acute trauma by inducing cellular autophagy [4 & ]. However, anorexia turns into a negative prognostic factor when it develops in patients affected by chronic diseases, including cancer [5] . In fact, long-lasting anorexia of chronic diseases, when compared with the short-term anorexia of acute diseases, is frequently associated to reduced food intake and weight loss, which increase the risk of complications and shorter survival. However, linking the clinical relevance of cancer anorexia only to its contributory role to reduced food intake and weight loss provides a limited view of the potential of anorexia [6 Cancer anorexia impairs patients' quality of life and is an independent negative prognostic factor [7 & ]. At presentation, loss of appetite is more frequently found in patients with lung cancer when compared with patients with gastrointestinal cancer, but weight loss is more prevalent in patients with gastrointestinal cancer than in patients with lung cancer [8] . This evidence strengthens the concept that cancer anorexia is not necessarily associated with reduced food intake and weight loss, and that its negative influence on the prognosis of cancer patients is related to more complex mechanisms than simple reduction of food intake [9] . Dissecting the clinical features of cancer anorexia and their pathophysiological correlates is a priority in the research of more effective prevention strategies and therapeutic options.
Cancer anorexia is a medical term, which encompasses a number of symptoms related to eating behavior. In general, the presence of cancer anorexia is clinically diagnosed when cancer patients refer any negative change of their appetite. However, more symptoms than the vaguely reported reduction of appetite concur to the definition of cancer anorexia and its clinical characterization (Table 1) .
In a series of more than 150 consecutive lung and gastrointestinal cancer patients with advanced disease, loss of appetite was the most common symptom (38%), but early satiety (27%) was also prevalent [8] . More recently, Barajas Galindo et al. [10 && ] studied cancer patients to determine the prevalence of different appetite disorders and their influence on dietary intake, nutritional status, and quality of life. Nutritional status was assessed using Subjective Global Assessment, anthropometry, and grip strength. Dietary intake was evaluated with a 24-h recall, and patients were questioned about the presence of changes in appetite (none, anorexia, early satiety, or both). Quality of life was measured using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. Among 128 cancer patients, 61.7% experienced changes in appetite. In more detail, 31% reported loss of appetite (anorexia), 13.3% early satiety, and 17.2% both. Appetite disorders were more common in women and with the presence of cachexia. The combination of anorexia and satiety resulted in a lower weight and BMI. However, there were no significant effects on energy or macronutrient intake among different appetite alterations. Patients with a combination of anorexia and early satiety had worse overall health perception, role function, and fatigue.
The importance to comprehensively assess disease-associated anorexia is highlighted by the different performance of diagnostic tools routinely used in clinical practice. Arezzo di Trifiletti et al. [11] studied hospitalized patients consecutively admitted to an Internal Medicine ward. Patients were asked to self-assess their appetite vs. the previous month. The visual analogue scale (VAS) and two large used questionnaires [european society for clinical nutrition and metabolism (ESPEN) score and Anorexia Questionnaire] were also submitted. Food intake was recorded, and nutritional (i.e., body weight, height), functional (i.e., handgrip strength), and clinical variables (i.e., length of stay) were registered upon admission and before discharge. Among 105 consecutive patients, the prevalence of anorexia as assessed by patients' self-assessment, ESPEN score, and the Anorexia Questionnaire was
KEY POINTS
Cancer anorexia is an independent negative prognostic factor in cancer patients.
Cancer anorexia is a general umbrella under which a series of nutrition-related symptoms and signs coexist.
Loss of appetite, early satiety, changes in taste and smell are the most frequently reported symptoms by anorectic cancer patients.
Specific pathophysiological mechanisms are being discovered underlying the different anorexiarelated symptoms.
Effective prevention and treatment of cancer anorexia should be based on the assessment and targeting of the contributory symptoms and signs. Anorexia is a medical term which should be considered as an umbrella under which a series of symptoms interfering with eating behavior are comprised. These symptoms may develop separately or they may concur. Consequently, the precise diagnosis and characterization of anorexia may depend on different diagnostic tools. VAS, visual analogue scale; FEES fiberoptic endoscopic evaluation of swallowing.
23, 10 and 48%, respectively. Visual analogue score did not show any correlation with food intake. Anorexic patients as identified by the self-assessment of appetite showed reduced food intake and weaker handgrip strength than nonanorexic. The ESPEN score correlated with body weight, food intake, and handgrip strength, but was not related with length of stay. Anorexic patients as identified by the Anorexia Questionnaire showed reduced food intake, lower body weight, weaker handgrip strength, and longer hospital stay than nonanorexic patients [11] . The prevalence of anorexia significantly varies according to the diagnostic tool used. Except for VAS, all the tested tools identify patients with impaired nutritional and functional variables. This important study further support the concept that in clinical practice, disorders of appetite reflects different underlying mechanisms whose impacts on clinical outcome measures may differ [11] .
Diagnosing cancer anorexia as the generic reduction/loss of appetite should therefore represent the first level of assessment in a multistep approach to precisely identify the clinical characteristics of the appetite disorder. This detailed assessment may then drive the more appropriate treatment. The clinical and scientific rationale for dissecting the features of cancer anorexia is also supported by recent data showing differential pathophysiological mechanisms for the different subcategories of cancer anorexia.
BRAIN INVOLVEMENT IN CANCER ANOREXIA
Cancer anorexia results from the functional impairment of the hypothalamic physiological mechanisms controlling eating behavior under normal conditions [12,13 & ]. In more detail, the inflammatory response following initiation and progression of cancer involves those brain areas controlling eating behavior. Neuroinflammation disrupts physiological modulation of the activities of hypothalamic satietymediating neurons (i.e., proopiomelanocortin neurons) and prophagic neurons [i.e., neuropeptide Y (NPY) neurons]. This results in chronic hyperactivation of proopiomelanocortin neurons and chronic inhibition of NPY neurons. Interestingly, these functional changes appear to also influence muscle loss and possibly gastric emptying (early satiety), and thus highlight the existence of brainmuscle axis which controls, at least in part, muscularity under physiological and pathological conditions [14 & ].
The pathogenesis of cancer anorexia has been largely investigated using animal models. In cancer patients, the use of invasive techniques to study in vivo the function of central appetite-regulating areas, including the hypothalamus, is limited by technical difficulties and ethical considerations.
Imaging techniques have been extensively used to assess brain function in psychiatric eating disorders and obesity [15] . Functional, molecular, and genetic neuroimaging has therefore highlighted the existence of brain anomalies and neural vulnerability factors related to obesity and eating disorders such as binge eating or anorexia nervosa. This new information opens the way to prevention studies using functional and molecular neuroimaging to perform early diagnostics and to phenotype subjects at risk by exploring different neurobehavioral dimensions of the food choices and motivation processes. Key neuroimaging techniques include functional MRI (fMRI), PET, single photon emission computed tomography, pharmacogenetic fMRI, and functional near-infrared spectroscopy. The evolution of these techniques has led to the development of noninvasive strategies to modulate foodrelated brain processes and functions [15] , including real-time fMRI neurofeedback, repetitive transcranial magnetic stimulation, and transcranial direct current stimulation.
Owing to the emerging role of supportive care in positively influencing long-term outcome of cancer patients receiving anticancer treatments [16 && ], imaging techniques have been also applied to the functional study of the neural correlates of cancer anorexia. Molfino et al. [17 && ] studied 13 anorexic (n ¼ 9) and nonanorexic (n ¼ 4) lung cancer patients. Hypothalamic activation was recorded in anorectic and nonanorectic patients and in controls (n ¼ 2) by fMRI, before, immediately after the administration of an oral nutritional supplement, and after 15 min. The grey of the hypothalamus and blood oxygen level dependent (BOLD) intensity were calculated and normalized for basal conditions. Results obtained showed that controls had the lowest BOLD intensity. At all-time points, anorexic patients showed lower hypothalamic activity compared with nonanorexic cancer patients. This study showed that hypothalamic activity in anorectic cancer patients is reduced respect to nonanorectic cancer patients and responds differently to oral challenges [17 && ]. This supports the hypothesis that a central control of appetite dysregulation during cancer anorexia exists, before, and after oral intake.
VISUAL CUES AND CANCER ANOREXIA
Food presentation is an important driver of eating behavior. Recently, Muto et al. [ 18 && ] used real-time imaging of neuronal activity in freely behaving or constrained zebrafish larvae to demonstrate that prey or prey-like visual stimuli activate the hypothalamic feeding center. They also identified prey detector neurons in the pretectal area that project to the hypothalamic feeding center. Ablation of the pretectum completely abolishes prey capture behavior and neurotoxin expression in the hypothalamic area also reduces feeding. Taken together, these results suggest that the pretecto-hypothalamic pathway plays a crucial role in conveying visual information to the feeding center. Thus, this pathway possibly converts visual food detection into feeding motivation in zebrafish 
CHANGES IN TASTE/SMELL AND CANCER ANOREXIA
In cancer patients, changes in taste and smell occur frequently, either before starting anticancer therapies or as a side-effect of chemotherapy and radiotherapy. Taste and smell changes may also occur in cancer survivors. They disrupt eating behavior by reducing global food intake and/or restricting intake only to specific foods. A clear example is meat aversion, which is a frequent symptom early reported by cancer patients. Meat aversion may or may not be associated to anticancer therapies, and it is related to changes in the taste and smell.
A ] recently studied taste and smell changes because of chemotherapy in testicular cancer patients before, during, and up to 1 year after cisplatin-based chemotherapy. In total, 21 consecutive testicular cancer patients and 48 healthy controls participated. Taste strips and 'Sniffin sticks' (MediSense, Sense Trading, Groningen, The Netherlands) were used to determine psychophysical taste and smell function. Subjective taste, smell, appetite, and hunger were assessed using a questionnaire. Dietary intake was analyzed using a food frequency questionnaire. Food preference was assessed using food pictures varying in taste (sweet/savory) and fat or protein content. A Dual-Energy X-ray Absorptiometry scan was performed to measure whole body composition [21 && ]. Compared with controls, cancer patients had a lower smell threshold and lower preference for high-fat sweet foods at baseline [21 && ]. Over time, intraindividual psychophysical taste and smell function was highly variable. The salty taste threshold increased at completion of chemotherapy compared to baseline. A transient decrease of subjective taste, appetite, and hunger feelings was observed per chemotherapy cycle. The percentage of fat mass increased during chemotherapy compared to baseline, whereas the lean mass and bone density decreased [21 && ]. This study suggests that coping strategies regarding subjective taste impairment should especially be provided during the first week of each chemotherapy cycle. Also, as the body composition of testicular cancer patients already had changed at completion of chemotherapy, intervention strategies to limit the impact of cardiovascular risk factors should probably start during treatment [21 && ].
INFLAMMATION AND CANCER ANOREXIA
Neuroinflammation appears a key factor in the ignition and progression of disorders of appetite in cancer patients ]. The aims of the study were to examine the relationships between inflammatory biomarkers and the Patient Reported Outcome Measures (PROMs) of pain, appetite, and fatigue; and to explore whether levels of baseline biomarkers were associated with changes in these PROMs following treatment with corticosteroids. Inclusion criteria were: more than 18 years, taking opioids for moderate or severe cancer pain; pain at least 4 (numerical rating scale 0-10). Serum was extracted and levels of inflammatory biomarkers were assessed. PROMs of pain, appetite, and fatigue were assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. Data were available on 49 patients. Levels of soluble TNF receptor1, interleukin (IL)-6, IL-18, macrophage migration inhibitory factor, macrophage chemotactic protein-1, transforming growth factor-b1, IL-1ra, and C-reactive protein and erythrocyte sedimentation rate were elevated; IL-1b, IL-2, IL-4, IL-8, IL-10, IL-12(p70), interferon-g, MIP-1a, and TNF-a were below the level of detection. The following correlations were observed: appetite and IL-6 and C-reactive protein; fatigue and IL-1ra [25 && ]. Therefore, in patients with advanced cancer and pain, some proinflammatory cytokines were related to appetite and fatigue.
The study supports the concept that appetite disorders during cancer is associated to increased inflammatory response. However, it remains to be established whether similar correlations could be also observed in patients with cancer anorexia without pretreatment with chemotherapy or radiotherapy.
CONCLUSION
Novel evidence from experimental studies and clinical trials highlight the importance of characterizing the complexity of disorders of appetite in cancer patients. Limiting the assessment of the presence of cancer anorexia to the investigation of generic changes of appetite may reduce the possibility to provide effective preventive and therapeutic strategies. It is acknowledged that the simple symptom 'My appetite has reduced' has strong prognostic value. However, its better characterization may help in identifying the pathophysiological mechanism(s) and effectively treating it. This is one of the few clinical studies investigating the relationship between circulating proinflammatory cytokines and appetite disorders in cancer patients. The limitation of the study is the type of cancer patients enrolled, that is, advanced cancer patients. It remains to be ascertained the relationship between pro-inflammatory cytokines and cancer anorexia in cancer patients at presentation and without anticancer treatments.
